Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
60.65
+0.92 (1.54%)
At close: Mar 31, 2026, 4:00 PM EDT
60.60
-0.05 (-0.08%)
After-hours: Mar 31, 2026, 7:57 PM EDT
BMY Revenue
In the year 2025, Bristol-Myers Squibb Company had annual revenue of $48.19B, down -0.22%. Bristol-Myers Squibb Company had revenue of $12.50B in the quarter ending December 31, 2025, with 1.30% growth.
Revenue (ttm)
$48.19B
Revenue Growth
-0.22%
P/S Ratio
2.57
Revenue / Employee
$1,482,892
Employees
32,500
Market Cap
123.83B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 48.19B | -106.00M | -0.22% |
| Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
| Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
| Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
| Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
| Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
| Dec 31, 2019 | 26.15B | 3.58B | 15.89% |
| Dec 31, 2018 | 22.56B | 1.79B | 8.59% |
| Dec 31, 2017 | 20.78B | 1.35B | 6.94% |
| Dec 31, 2016 | 19.43B | 2.87B | 17.31% |
| Dec 31, 2015 | 16.56B | 681.00M | 4.29% |
| Dec 31, 2014 | 15.88B | -506.00M | -3.09% |
| Dec 31, 2013 | 16.39B | -1.24B | -7.01% |
| Dec 31, 2012 | 17.62B | -3.62B | -17.05% |
| Dec 31, 2011 | 21.24B | 1.76B | 9.03% |
| Dec 31, 2010 | 19.48B | 676.00M | 3.59% |
| Dec 31, 2009 | 18.81B | 1.09B | 6.17% |
| Dec 31, 2008 | 17.72B | 2.10B | 13.43% |
| Dec 31, 2007 | 15.62B | -591.00M | -3.65% |
| Dec 31, 2006 | 16.21B | -2.40B | -12.88% |
| Dec 31, 2005 | 18.61B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| AstraZeneca | 58.74B |
| Novartis AG | 56.67B |
| Sanofi | 54.85B |
| Novo Nordisk | 48.59B |
| GSK plc | 43.97B |
BMY News
- 19 hours ago - Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years - Business Wire
- 2 days ago - Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) - Business Wire
- 3 days ago - Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride) - Business Wire
- 7 days ago - Bristol-Myers Squibb: Dividend/Portfolio Renewal Thesis Remains Promising - Seeking Alpha
- 8 days ago - Bristol-Myers Squibb: An Attractive High-Yield Stock Amid Market Uncertainty - Seeking Alpha
- 8 days ago - Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26) - Business Wire
- 11 days ago - Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab) - Business Wire
- 11 days ago - Bristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma - Benzinga